Pharmaceutical company Merck (NYSE:MRK) is set to report its second quarter earnings on Tuesday, July 29th, before the ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. Merck & Co., Inc. (NYSE:MRK ...

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Tuesday before market open. Here’s what ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently ...

Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

Merck is undervalued with strong growth, profitability, and credit strength despite CDMO challenges, offering compelling ...

Learn about the executive team and board of directors at Merck & Co Inc (MRK:XNYS) and review their bios and compensation over the latest fiscal years.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of chronic obstructive pulmonary disease treatments with Verona Pharma’s ...